Drugs / Mechanobiologically Reprogrammed Macrophage-Derived Exosomes
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07563972 | May 2026 → Mar 2027 expected | neoplasm | West China Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mechanobiologically Reprogrammed Macrophage-Derived Exosomes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07563972 ↗ |
| Known as | MRMEs | “intratumoral injection of mechanically reprogrammed macrophage-derived exosomes (MRMEs) in adults aged 18-65 years with advanced solid tumors” NCT07563972 ↗ |
| Modality | Other / unclassified | “macrophage-derived exosomes” NCT07563972 ↗ |
| Route | Other | “Administered via intratumoral injection” NCT07563972 ↗ |